TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.
Also called NCT03354663
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 156 participants
- Sponsor
- Registry
-
NCT03354663
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Germany, Italy
- Registry status
- Completed
Technical summary
Registry record NCT03354663. Allocation not applicable; no masking; primary purpose treatment. Start 2017-12-11 (actual); primary completion 2018-08-02 (actual). Results posted on 2019-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
- Acronym
- TactiSense
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Device)
- TactiCath SE
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct03354663- Content hash
e30a990e101c916736d76c19bf52ef20122a8893d1df1dfe3ed137e3bee8d08d